Contact Us

Contact us with any questions or comments regarding our novel approach to treating infectious, inflammatory, and degenerative diseases with our plasma gelsolin technology platform.

Name

Phone

Organization

Role

Scientist/Academic Media Investor Other

Message

Stay informed of our latest discoveries and news.

GENERAL NEWS/MEDIA

February 2021: NIH and Other Independent Studies Confirm Low Levels of BioAegis’ ‘Inflammation Regulator Protein,’ Gelsolin, Associated with COVID-19 Severity

February 2, 2021

November 2020: BioAegis Therapeutics Expands Phase 2 COVID-19 Treatment Clinical Trial in EU for Inflammation Regulator

November 15, 2020

September 2020: BioAegis Therapeutics Announces Study Indicating Gelsolin Treatment Improves Survival and Reduces Lung Injury in Antibiotic Resistant Pneumonia

September 4, 2020

August 2020: Independent Studies Confirm Low Levels of Immune System Protein, Gelsolin, Associated with COVID-19 Severity

August 17, 2020

October 6-7, 2020: BioNJ’s 10th Annual BioPartnering Conference

August 20, 2020: WIB-Metro New York – Biotech Leadership in the time of COVID-19: Impact, Opportunity, and Resilience

Tweets by BioAegis

COMPANY DETAILS

LOCATION:
BioAegis Therapeutics
North Brunswick, NJ

MEDIA INQUIRIES:
Contact: Christine Lagana
clagana@bioaegistx.com

INVESTOR INQUIRIES:
Contact: Steven Cordovano
scordovano@bioaegistx.com

JOIN OUR TEAM

Facebook

Twitter

Youtube

We have expanded our COVID-19 treatment phase 2 clinical trial footprint within the EU.-

Contact Us

Stay informed of our latest discoveries and news.

COMPANY DETAILS

FOLLOW US